SML0211

iCRT3

≥98% (HPLC), Wnt / b-catenin pathway inhibitor, powder

• Synonyme(s) : 2-[[[2-(4-ethylphenyl)-5-methyl-4-oxazolyl]methyl]thio]-N-(2-phenylethyl)acetamide
• Formule empirique (notation de Hill) : C₂₃H₂₆N₂O₂S
• Numéro CAS: 901751-47-1
• Poids moléculaire : 394.53
• UNSPSC Code: 12352200
• PubChem Substance ID: 329825232
• NACRES: NA.77
• MDL number: MFCD14766288
• Assay: ≥98% (HPLC)
• Form: powder
• Storage condition: desiccated

Propriétés

• Nom du produit: iCRT3,
• assay: ≥98% (HPLC)
• Quality Segment: 100
• form: powder
• storage condition: desiccated
• color: white to tan
• solubility: DMSO: ≥5 mg/mL
• storage temp.: 2-8°C
• SMILES string: CCc1ccc(cc1)-c2nc(CSCC(=O)NCCc3ccccc3)c(C)o2
• InChI: 1S/C23H26N2O2S/c1-3-18-9-11-20(12-10-18)23-25-21(17(2)27-23)15-28-16-22(26)24-14-13-19-7-5-4-6-8-19/h4-12H,3,13-16H2,1-2H3,(H,24,26)
• InChI key: QTDYVSIBWGVBKU-UHFFFAOYSA-N

Description

General description

iCRT3 is a small cell-permeable oxazole compound. It blocks cytokine secretion in lipopolysaccharide (LPS)-stimulated macrophages.

Application

iCRT3 has been used to inhibit the interactions between β-catenin and transcription factor (TCF).

iCRT3 has been used:

• for β- catenin inhibition in dual luciferase assay
• to inhibit β-catenin /TCF interactions and their transcriptional activity
• as wingless/tailess (wnt) antagonist, to determine Wnt/β-catenin signaling is essential for PROX1-mediated regulation of forkhead box protein C2 (FOXC2)(3)catenin inhibition in dual luciferase assay
• to inhibit β- catenin /TCF interactions and their transcriptional activity
• as wingless/tailess (wnt) antagonist, to determine Wnt/β-catenin signaling is essential for PROX1-mediated regulation of forkhead box protein C2 (FOXC2)

Biochem/physiol Actions

The key mediator of Wnt signaling is the transcriptional co-activator b-catenin. In the cytoplasm, b-catenin is tightly bound to a complex that includes Axin and GSK-3b. Stimulation causes b-catenin stabilization, translocation to the nucleus and association with TCF4 to initiate transcription of responsive genes, referred to as Catenin Responsive Transcription (CRT). Virtually all Wnt-associated cancers are the result of misregulated CRT. Three inhibitors of CRT (iCRT) were identified in a screen that employed RNAi based knockdown of Axin, which stimulates CRT without affecting upstream mechanisms such as GSK activity, transduction by disheveled / frizzled, etc. These compounds are potent inhibitors of CRT reporter genes, as well as endogenous gene targets. The compounds also disrupt b-catenin-TCF4 interaction in a dose dependent manner, and cause G0/G1 arrest in colon tumor lines.

Wnt / b-catenin pathway inhibitor

Informations sur la sécurité

• Classe de stockage: 11 - Combustible Solids
• wgk: WGK 3